Sugi Predict

Sugi Predict / Compounds / SCHEMBL5076232

SCHEMBL5076232

SCHEMBL5076232

Nc1nc(=O)n([C@H]2CC[C@@H](CO)O2)cc1NC=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.45
▸ RIN1 Q13671 1/20 0.45
▸ ALB P02768 4/20 0.42
▸ LMNA P02545 4/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CYP1A2 P05177 1/20 0.39
▸ DNMT1 P26358 5/20 0.38
▸ CACNA1F O60840 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ CACNA1D Q01668 2/20 0.34
▸ CACNA1S Q13698 2/20 0.34
▸ CACNA1C Q13936 2/20 0.34
▸ PDE3A Q14432 2/20 0.34
▸ ADRB1 P08588 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ FPR2 P25090 1/20 0.33
▸ DNMT3B Q9UBC3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9803735 0.83 ABL1 (0.47) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL5953793 0.82 ABL1 (0.47) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL5953796 0.82 ABL1 (0.47) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL3451324 0.82 ABL1 (0.47) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL14389424 0.82 ABL1 (0.47) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL20633178 0.82 ABL1 (0.47) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL24695854 0.81 ALB (0.63) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL3437075 0.81 ABL1 (0.46) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL913431 0.81 ALB (0.63) ABL1RIN1ALBLMNAALDH1A1
SCHEMBL10379562 0.81 ABL1 (0.46) ABL1RIN1ALBLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides SCHINAZI RAYMOND F 2008-11-27 — — US claimed
US-20040167140-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides EMORY UNIVERSITY 2004-08-26 — — US claimed
EP-1361227-A2 [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides Emory University (US) 2003-11-12 — — EP claimed
US-20020198173-A1 [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides EMORY UNIVERSITY 2002-12-26 — — US claimed
EP-0805683-A4 5-CARBOXAMIDO OR 5-FLUORO]- 2',3'-UNSATURATED OR 3'-MODIFIED]-PYRIMIDINE NUCLEOSIDES UNIV EMORY (US) 1999-09-01 — — EP claimed
EP-0805683-A1 5-CARBOXAMIDO OR 5-FLUORO]- 2',3'-UNSATURATED OR 3'-MODIFIED]-PYRIMIDINE NUCLEOSIDES EMORY UNIVERSITY (US) 1997-11-12 — — EP claimed
WO-1996022778-A1 DERIVATIVES OF SUCCINAMIDE AND THEIR USE AS METALLOPROTEINASE INHIBITOR EMORY UNIVERSITY (US) 1996-08-01 — — WO claimed
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides SCHINAZI RAYMOND F 2008-11-27 — — US disclosed
US-7419966-B2 [5-carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides EMORY UNIVERSITY (US) 2008-09-02 — — US disclosed
US-20040167140-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides EMORY UNIVERSITY 2004-08-26 — — US disclosed
US-6680303-B2 VIRICIDES FOR TREATING HIV AND HEPATITIS VIRUS EMORY UNIVERSITY 2004-01-20 — — US disclosed
EP-1361227-A2 [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides Emory University (US) 2003-11-12 — — EP disclosed
US-20020198173-A1 [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides EMORY UNIVERSITY 2002-12-26 — — US disclosed
US-6391859-B1 HUMAN IMMUNODEFICIENCY VIRUS; VIRICIDES EMORY UNIVERSITY 2002-05-21 — — US disclosed
US-6232300-B1 ADMINISTERING AS HEPATITIS B VIRICIDE EMORY UNIVERSITY 2001-05-15 — — US disclosed
EP-0805683-A4 5-CARBOXAMIDO OR 5-FLUORO]- 2',3'-UNSATURATED OR 3'-MODIFIED]-PYRIMIDINE NUCLEOSIDES UNIV EMORY (US) 1999-09-01 — — EP disclosed
US-5905070-A HUMAN T-CELL LEUKEMIA/LYMPHOMA AND HEPATITIS B VIRICIDES; AIDS EMORY UNIVERSITY (US) 1999-05-18 — — US disclosed
US-5703058-A TREATMENT OF HIV AND HEPATITIS B EMORY UNIVERSITY (US) 1997-12-30 — — US disclosed
EP-0805683-A1 5-CARBOXAMIDO OR 5-FLUORO]- 2',3'-UNSATURATED OR 3'-MODIFIED]-PYRIMIDINE NUCLEOSIDES EMORY UNIVERSITY (US) 1997-11-12 — — EP disclosed
WO-1996022778-A1 DERIVATIVES OF SUCCINAMIDE AND THEIR USE AS METALLOPROTEINASE INHIBITOR EMORY UNIVERSITY (US) 1996-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides DUT, NUDT1, PNP ABL1 2760/4885RIN1 3979/4885ALB 1099/4885
US-20020198173-A1 [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides DUT, NUDT1, PNP ABL1 3147/4885RIN1 3990/4885ALB 1169/4885
US-20040167140-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides DUT, NUDT1, PNP ABL1 3147/4885RIN1 3990/4885ALB 1169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.